Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06979726

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06979726
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06979726. Allocation not applicable; no masking; primary purpose treatment. Start 2025-11-20 (actual); primary completion 2026-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
Acronym
GatorScalesWHF
Condition
Heart Failure
Condition
Volume Overload
Intervention (Drug)
Lasix ONYU
Lead sponsor
University of Florida (class: other)
Collaborator
SQ Innovation, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06979726
Content hash
46237fc8078a090871d63793ec90c515664d541b46c1ba89b4e42db466c8dd6d